Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Istaroxime

Generic Name: Istaroxime

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₂N_₂O_₃

CAS Number: 203737-93-3

Unique Ingredient Identifier: W8I9H2TPPL

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in heart disease.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

Phase 1

Recruiting

Posted: 2023/08/03

Sponsor:Windtree Therapeutic...

ID:NCT05975021

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

Phase 2

Completed

Posted: 2020/03/27

Sponsor:Windtree Therapeutic...

ID:NCT04325035

Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a

Early Phase 1

Completed

Posted: 2016/05/13

Sponsor:

Benjamin Levine

ID:NCT02772068

The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure

Phase 2

Completed

Posted: 2015/12/01

Sponsor:Windtree Therapeutic...

ID:NCT02617446

Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

Phase 1

Posted: 2015/06/22

Sponsor:

Lee's Pharmaceutical...

ID:NCT02477449

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Windtree Therapeutics Partners with Evofem to Manufacture FDA-Approved Contraceptive PHEXXI

2 months ago

Windtree Therapeutics has entered into a License and Supply Agreement with Evofem Biosciences to become the sourcing partner for PHEXXI, a hormone-free contraceptive vaginal gel that generated over $19 million in annual revenue in 2024.

Gilead's Trodelvy Receives FDA Breakthrough Therapy Designation for SCLC; Seladelpar Recommended for EU Approval

5 months ago

The FDA granted Breakthrough Therapy Designation to Gilead's Trodelvy for extensive-stage small cell lung cancer (ES-SCLC) after platinum-based chemotherapy, based on promising results from the TROPiCS-03 study.

Windtree's Istaroxime Shows Promise in Cardiogenic Shock Treatment and Arrhythmia Prevention

5 months ago

Alexandre Mebazaa presented positive Phase 2b data on istaroxime for early cardiogenic shock at the Cardiovascular Clinical Trials Conference.

Windtree Therapeutics Partners with New Growth Advisors to Explore Strategic Options for Istaroxime

6 months ago

Windtree Therapeutics has engaged New Growth Advisors to explore strategic options for its cardiovascular portfolio, including istaroxime, following positive Phase 2 results.

Windtree and Intensity Therapeutics Report Progress in Heart Failure and Oncology

6 months ago

Windtree Therapeutics reported positive Phase 2b results for istaroxime in early cardiogenic shock, showing significant improvements in cardiac function and blood pressure.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy